Approved Human Study Sets Up Pivotal Test for Aging Theory from Harvard’s David Sinclair

In a major proving ground test for the longevity field, the FDA has given its approval for a human trial for a gene therapy attempting a near-total rejuvenating reset of cells.

(David Sinclair, Michael Ringel, Sharon Rosenzweig-Lipson, and Jerry McLaughlin of Life Biosciences | Longevity.technology)

The FDA has greenlighted Life Biosciences’ first human trial testing whether their gene therapy can confer a near-total rejuvenating reset of cells.

Clinical Trials

Biohacking Expert Ben Greenfield Showcases How to Affordably Biohack Your Home

The biohacker and New York Times bestselling author Ben Greenfield details affordable biohacking methods for the kitchen, living room, and bedroom.

(Biohacker and New York Times bestselling author Ben Greenfield | Medium)

Biohacker and New York Times bestselling author Ben Greenfield provides budget-friendly tips on how to biohack your home using nutrition in the kitchen, stretching devices in the living room, and a deep rest-inducing nerve stimulator in the bedroom.

Others

Disarm Therapeutics finds a compound that inhibits SARM1, an enzyme responsible for nerve projection deterioration. 

Disarm Therapeutics has discovered a drug that inhibits SARM1, an enzyme that causes nerve projection loss.

The NAD+-consuming enzyme SARM1 is a therapeutic candidate for retinal diseases and vision loss.

The NAD+ consuming enzyme SARM1 is a candidate therapeutic target for vision loss and other retinal diseases.

Search Result: nerve fiber

FDA Greenlights Life Biosciences’ Human Study, Setting Up Pivotal Test for Aging Theory from Harvard’s David Sinclair

Biohacking Expert Ben Greenfield Showcases How to Affordably Biohack Your Home

Eli Lilly & Company’s Small Molecule Prevents Neurodegeneration

Researchers Pinpoint the Cause of a Disease that Leads to Childhood-Blindness